| |
Accelerate miRNA biomarker discoveries with our genomics services
Learn how 
|
|
Today's Big NewsSep 30, 2022 |
Florida healthcare organizations reported that thousands of patients have been moved or are still in the process of being evacuated two days after Hurricane Ian made landfall and crossed the center of the state. While most hospitals have not seen significant damage, the larger challenges have been disruptions to electrical grids and water supplies. After a long road filled with scrutiny and uncertainty, Amylyx’s drug for ALS has finally scored FDA approval. Dubbed Relyvrio, it's the first treatment that showed significant slowing in both disease progression and functional decline, and it extended survival in a randomized clinical trial. Now, for only the cost of a few dozen cheeseburgers, you could have a fully sequenced human genome. Illumina is rolling out a new line of DNA analyzers that it says can read a person’s entire genetic code for about $200. - Conor Hale |
|
Tuesday, October 4, 2022 | 1pm ET / 10am PT This panel will discuss leveraging technology and home health solutions to augment existing points of care between patients and their clinical care team to improve the patient experience, drive more scientific rigor to data generation and achieve timely endpoint capture. Register now. 
|
|
| By Dave Muoio Utility interruptions and long-term shortages of downstream care capacity are among the top concerns for the head of the Florida Hospital Association. |
|
|
|
By Zoey Becker After a long and winding road filled with AdComms, the FDA has finally approved Amylyx's ALS drug, Relyvrio. In an interview with Fierce Pharma, the company's co-founders say there is more research to be done and more drugs to be made to meet the unmet needs of ALS patients. |
By Conor Hale Now, for only the cost of a few dozen cheeseburgers, you could have a fully sequenced human genome. |
By Max Bayer Nearly six months after slashing more than a third of its workforce, Solid Biosciences is hoping to get on firmer footing through addition, not subtraction. The company is acquiring fellow gene therapy developer AavantiBio and raking in $75 million in new financing. |
|
Tuesday, October 4, 2022 | 2pm ET / 11am PT In this webinar we will cover the challenges that this collaboration aims to solve and how the partnership is poised to enable significant scientific outcomes. We will also take your questions live about this exciting advancement. Register now. 
|
|
By Max Bayer Merck's Keytruda has dazzled since first nabbing approval in 2014, earning billions of dollars in revenue and expanding its reach to more than a dozen cancers. But as the drug's patent expiration nears, can Merck manufacture a second clinical lightning strike? |
By Heather Landi Google's cloud division has teamed up with Fitbit to roll out a new service to help hospitals integrate and analyze wearables data. |
By Max Bayer Just a month after two top executives announced their departure, Scandion posted a phase 2 flop of its sole asset. The company says SCO-101 failed to produce a high enough tumor reduction rate to pass the trial's primary endpoint. |
By Angus Liu The path to a potential NASH drug approval just got bumpier for Intercept Pharmaceuticals. Just as the company plans an FDA resubmission for Ocaliva for patients with milder disease, the drug has failed in a more advanced population. |
By Robert King Congress passed a short-term spending bill which extends two key rural hospital programs through Dec. 16, but does not touch looming pay cuts to doctors set to take effect next year. |
By Nick Paul Taylor Zealand Pharma’s phase 3 short bowel syndrome study has hit its primary endpoint, delivering data that could equip it to seek approval for a challenger to Takeda’s Gattex. |
By Conor Hale The agency’s green light expands the company’s AIR Recon DL programs from 2D to 3D imaging sequences, eliminating the need to take multiple 2D scans to reach a diagnosis in certain cases. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk with many of the Fierce 15 honorees to find out what makes them unique. We also share highlights from the Fierce Biotech Summit on gene editing innovations and battling biotech's bear market. |
|
|---|
|
|
|
Wednesday, October 5, 2022 | 11am ET / 8am PT This webinar will cover the needs and challenges of precision medicine from a clinical perspective, and present the economic values of employing a single cell technology for better patient stratification. Register now. 
|
|
eBook Improve your congress competitive intelligence and cut down costs by 50% Sponsored by: Ferma.AI, a Product of ZoomRx |
Executive Summary How a new app brings the power of CRM to a leading lab instruments provider’s field service engineers Sponsored by: Cognizant |
Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
Whitepaper Advanced research requires advanced tools. The next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Sponsored by: Bio-Techne |
eBook Improve patient engagement, adherence, and outcomes Sponsored by: Health Catalyst |
Video Can an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
Video Learn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
Whitepaper What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
Research Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
Whitepaper How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
Webinar Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
Whitepaper How can we predict the ability of a preclinical drug to inadvertently cause or intentionally inhibit cytokine secretion and T cell activation Sponsored by: ReachBio | The Cell Biology Experts™ |
Whitepaper Read our whitepaper and dive into the way healthcare providers can digitally transform day-to-day work by streamlining costs and increasing agility by removing manual paper burdens. Sponsored by: DocuSign |
Research Learn how a private health insurance company uses analytics to deliver exceptional service to its employees and members Sponsored by: Genpact |
Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
Whitepaper This paper explores how Medical Affairs is increasingly playing a key leadership role in evidence planning and generation (part 3 in a series). Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
Research TwinRCTs require fewer patients and shorten trial timelines for rare neurodegenerative diseases. Sponsored by: Unlearn AI |
eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
